Equities

Medimi AB

Medimi AB

Actions
  • Price (EUR)0.0004
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-83.40%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medimi AB, formerly MedicPen Aktiebolag (publ) is a Sweden-based company operating within healthcare and pharmaceutical industries. Medimi develops solutions that provide healthcare recipients and staff with drug management. The business focus is to develop, manufacture and sell products that facilitate patient medication. The products are sold under separate brands and include systems for medication assistance that send alarms at missed doses to relatives or caregivers, and the Company manufactures stationary tablet dispensers. The solution covers the entire chain, from doctors to dispensing at home. The products are at the forefront of technology and are developed for integration into IT environments.

  • Revenue in SEK (TTM)3.90m
  • Net income in SEK-13.85m
  • Incorporated1999
  • Employees6.00
  • Location
    Medimi ABIdeon Science ParkScheelevagen 17, Beta 6LUND 223 63SwedenSWE
  • Phone+46 40100800
  • Fax+46 40416328
  • Websitehttps://www.medimiab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.